The company's technology enables the measurement of biomarker concentration in tissue sections with subcellular resolution. Their proprietary AQUA® technology allows for objective and reproducible analysis of proteins in tissue, providing insights into cancer treatment. HistoRx is focused on advancing individualized patient care through the development of theranostic solutions. In 2012, the company was acquired by Genoptix, although the terms of the transaction were not disclosed.